Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Puslapis 1 nuo 21 rezultatus
Levodopa attenuates cellular apoptosis in steroid-associated necrosis of the femoral head.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The present study aimed to investigate the effects of levodopa (LEV) on cellular apoptosis in a rabbit model of steroid-associated necrosis of the femoral head (SANFH). A total of 44 healthy adult Chinese rabbits were randomly divided into three groups: Group A (n=15), administered a combination of
Levodopa neurotoxicity: experimental studies versus clinical relevance.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Levodopa therapy remains the major form of treatment for the symptoms of Parkinson's disease (PD). However, there has been a suspicion that its use may hasten the progression of nigral cell degeneration. This concept is based on the ability of levodopa to generate reactive oxygen species and the
Putaminal necrosis presenting with hemidystonia.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
A 7-year-old female presented with putaminal necrosis associated with hemidystonia. Cranial magnetic resonance imaging revealed bilateral putaminal lesions appearing as hypointense signals on T(1)-weighted images and hyperintense signals on T(2)-weighted images. After a differential diagnosis of
Fullerene C60 and ascorbic acid protect cultured chromaffin cells against levodopa toxicity.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Adrenal chromaffin cell (ACC) transplants, alone or combined with levodopa treatment, were used in attempted therapy for Parkinson's disease (PD). In a previous study, we demonstrated that levodopa caused chromaffin cell death either by necrosis or by apoptosis in cell culture. Here we report the
Efficacy of pramipexole combined with levodopa for Parkinson's disease treatment and their effects on QOL and serum TNF- α levels
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Purpose: To investigate the efficacy of combining the dopamine receptor agonist pramipexole with levodopa for Parkinson's disease (PD) treatment and to measure their effects on quality of life and tumor necrosis factor (TNF)-α levels in
Ninety-day Local Tolerability and Toxicity Study of ND0612, a Novel Formulation of Levodopa/Carbidopa, Administered by Subcutaneous Continuous Infusion in Minipigs.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
A 90-day study in Göttingen minipigs was conducted to test the local tolerability and systemic toxicity of ND0612, a novel aqueous solution of carbidopa (CD)/levodopa (LD) intended for the treatment of Parkinson's disease by continuous subcutaneous administration using a discrete infusion pump. To
Association of Parkinson's disease-related pain with plasma interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-α.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
OBJECTIVE
To study the association between Parkinson's disease (PD)-related pain and plasma interleukin (IL)‑1, IL‑6, IL‑10, and tumour necrosis factor (TNF)‑α levels.
METHODS
Sixty-seven participants were enrolled. Plasma inflammatory cytokine levels of IL-1, IL-6, IL-10, and TNF-α were measured
Lauric acid: Its role in behavioral modulation, neuro-inflammatory and oxidative stress markers in haloperidol induced Parkinson's disease
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The study was designed to investigate the neuro-protection of lauric acid (LA) on haloperidol (HPD) induced Parkinson's disease (PkD) rat model. Rats were divided into group A (normal), group B (diseased, by HPD 1mg/kg i.p. for 14 days), group C (standard treatment, levodopa 30 mg/kg), group D
Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The main lesion in Parkinson disease (PD) is loss of substantia nigra dopaminergic neurons. Levodopa (L-DOPA) is the most widely used therapy, but it does not arrest disease progression. Some possible contributing factors to the continuing neuronal loss are oxidative stress, including oxidation of
Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND
The pathogenesis of substantia nigra pars compacta neuronal injury in Parkinson disease (PD) remains unknown. Cerebrospinal fluid (CSF) has been reported to contain factors toxic to dopaminergic neurons.
OBJECTIVE
To determine whether the cytotoxic effects of CSF of PD patients are
Non-Occlusive Mesenteric Ischemia (NOMI) in Parkinson's disease: case report.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Non-occlusive mesenteric ischemia (NOMI) is a severe pathological condition characterized by signs and symptoms of bowel obstruction, intestinal necrosis resulting from acute and/or chronic inadequate blood perfusion, in the absence of an organic vascular obstruction detectable by imaging
Vitamin B12-impaired metabolism produces apoptosis and Parkinson phenotype in rats expressing the transcobalamin-oleosin chimera in substantia nigra.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND
Vitamin B12 is indispensable for proper brain functioning and cytosolic synthesis of S-adenosylmethionine. Whether its deficiency produces effects on viability and apoptosis of neurons remains unknown. There is a particular interest in investigating these effects in Parkinson disease
Heterotopic Ossification following Total Elbow Arthroplasty in a Patient with Parkinson's Disease: Case Report and Literature Review.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Introduction. Heterotopic ossification (HO) usually develops following surgery or trauma. Risk factors for HO following elbow fractures include delay to surgery (>7 days), floating fractures, and elbow subluxation. Systemic risk factors for HO include male sex; concurrent cranial,
Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Entacapone and tolcapone, novel catechol-O-methyl-transferase (COMT) inhibitors, have been developed for the treatment of Parkinson's disease in combination with levodopa. Three fatal cases of drug-induced hepatitis, one with hepatic necrosis and mitochondrial changes have been reported in clinical
[Sporadic cerebral amyloid angiopathy presenting with dementia and prominent capillary beta-amyloid deposition: a case report].
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
We report a sporadic case of unusual cerebral amyloid angiopathy (CAA) with prominent capillary involvement. A 67-year-old doctor developed gait disturbance, resting tremor and rigidity. He was diagnosed to have Parkinson's disease, for which the treatment with levodopa was effective. Four years
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
- Dirba 55 kalbomis
- Žolelių gydymas, paremtas mokslu
- Vaistažolių atpažinimas pagal vaizdą
- Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
- Skaitykite mokslines publikacijas, susijusias su jūsų paieška
- Ieškokite vaistinių žolelių pagal jų poveikį
- Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais
